• Home
• Media centre
• Pandemic flu
• H5N1 (avian) flu press releases

H5N1 (avian) flu press releases

29 January 2009
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

21 November 2008
GSK and Neptunus sign cooperation agreement to form joint venture for the co-development of flu vaccines in China, Hong Kong and Macau

16 September 2008
New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning

19 May 2008
First pre-pandemic vaccine approved to help protect against pandemic influenza

14 May 2008
Scientists publishing in Nature call for the diversification of antiviral stockpiles in preparation for an influenza pandemic

21 February 2008
GSK's candidate adjuvanted pre-pandemic H5N1 vaccine reaches important EU regulatory milestone

16 August 2007
GlaxoSmithKline signs contract for its pandemic flu vaccine with UK Government

3 August 2007
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen

13 June 2007
GlaxoSmithKline to make unprecedented vaccine donation to WHO pandemic flu stockpile

2 May 2007
GlaxoSmithKline supports World Health Organization efforts to strengthen global pandemic preparedness plans

5 March 2007
New studies indicate GSK’s pre-pandemic influenza vaccine can protect against different strains of H5N1

29 January 2007
GlaxoSmithKline files its new pre-pandemic influenza vaccine in Europe

17 January 2007
GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development: Company begins government and retail shipments of its antiviral Relenza®

15 December 2006
GlaxoSmithKline reaches EU regulatory milestone in its flu pandemic vaccine development programme

20 November 2006
GSK to supply and store H5N1 vaccine products for US flu pandemic stockpiling

13 November 2006
GSK joins with HHS and CDC to encourage flu vaccinations

18 October 2006
GlaxoSmithKline's new generation flu vaccine shows a significant increase in seroprotection rate in the over 65 population

18 October 2006
Switzerland to purchase GSK's H5N1 vaccine for pre-pandemic use

5 October 2006
GSK's new flu vaccine, FluLaval, provides Americans with a new option for fighting the flu

28 September 2006
GlaxoSmithKline grants license for manufacture of influenza treatment zanamivir

24 August 2006
GlaxoSmithKline receives approval in 15 European countries for use of Relenza in prevention of influenza A and B

26 July 2006
GSK reports significant advance in H5N1 pandemic flu vaccine programme

20 July 2006
GSK announces US Government purchase of Relenza for state stockpiles

4 May 2006
GlaxoSmithKline awarded $274 million HHS contract

23 March 2006
GlaxoSmithKline submits Biologics license application for FDA approval of Flulaval